Evidence Does NOT Support Avoiding Statins Due to Fracture Risk
The current evidence does not support withholding statin therapy based on fracture concerns - in fact, the relationship between statins and fractures remains controversial with no definitive evidence that statins increase fracture risk, and some data suggesting potential protective effects at appropriate doses.
The Evidence Landscape
What the Guidelines Say
The 2020 JAGS systematic review of 18 international cardiovascular disease prevention guidelines found no recommendations to discontinue statins specifically due to fracture risk 1. The guidelines identified only three scenarios for statin discontinuation in older adults:
- Statin intolerance (muscle symptoms, elevated liver enzymes)
- Poor health status with limited life expectancy
- Lack of ongoing cardiovascular benefit
Fractures are not mentioned as a reason to avoid or discontinue statins in any major guideline.
The Research Evidence is Mixed, Not Harmful
The relationship between statins and fractures shows conflicting but largely neutral-to-protective findings:
Studies showing NO increased fracture risk:
- The 2003 Women's Health Initiative study of 93,716 postmenopausal women found statin use was not associated with increased fracture risk (HR 1.22 for hip fracture, CI 0.83-1.81) 2
- A 2019 meta-analysis of RCTs showed no effect on fracture risk (RR 1.00,95% CI 0.87-1.15) 3
- A 2025 Manitoba BMD Registry study of 22,393 individuals found no clinically meaningful effect of statin use on bone density, even with high adherence over several years 4
Studies showing potential PROTECTIVE effects:
- A 2023 Korean study of 365,656 elderly patients found statin use associated with reduced fracture risk (HR 0.77 for major osteoporotic fractures, 0.49 for hip fractures) with age-, dose-, and duration-dependent benefits 5
- A 2024 Mendelian randomization study supported a protective effect of HMGCR-mediated cholesterol reduction against osteoporosis 6
The Dose-Dependency Nuance
The most important finding is that dose matters:
- A 2019 Austrian study found low-dose statins (0-10 mg/day) were associated with underrepresentation of osteoporosis (OR 0.39-0.70) 7
- High-dose statins (>40 mg simvastatin, >20 mg atorvastatin/rosuvastatin) showed overrepresentation of osteoporosis (OR 1.64-2.04) 7
This suggests a U-shaped relationship where moderate doses may be neutral or protective, while very high doses might theoretically increase risk.
Clinical Implications
When to Consider Statin Deprescribing in Older Adults
Base decisions on these factors, NOT fracture risk:
- Age ≥85 years with no established cardiovascular disease
- Limited life expectancy (<1-2 years)
- Poor functional status or advanced dementia
- Statin intolerance (confirmed myopathy, not just myalgias)
- Patient preference after shared decision-making
The Real Concern: Rare Statin-Induced Myopathy
The one legitimate fracture-related concern is statin-induced necrotizing myopathy, which can cause:
- Profound muscle weakness leading to falls
- Functional decline
- Secondary fragility fractures from falls 8
However, this is extremely rare and typically occurs with:
- Medication errors (taking double doses)
- Very high doses
- Drug interactions
- Genetic predisposition
Common Pitfalls to Avoid
- Don't conflate correlation with causation: Older adults on statins have more cardiovascular disease and are frailer - they're at higher baseline fracture risk regardless of statin use
- Don't extrapolate from observational data: The RCT evidence shows no fracture harm 3
- Don't use fracture risk as a reason to avoid cardiovascular protection: The cardiovascular mortality benefit in appropriate patients far outweighs theoretical fracture concerns
- Don't ignore the dose-dependency: If concerned, use moderate doses rather than avoiding statins entirely 7
The Bottom Line
Continue statins in patients with clear cardiovascular indications, regardless of osteoporosis or fracture history. The evidence does not support fracture risk as a contraindication to statin therapy. Focus deprescribing decisions on life expectancy, functional status, and cardiovascular benefit rather than theoretical bone concerns 1.